TY - JOUR AB - BACKGROUND: Cardiovascular diseases are the leading cause of death. Pharmacist-led medication review with follow-up might be cost-effective preventing cardiovascular diseases. OBJECTIVE: To undertake a cost-utility analysis of the addition of pharmacist-led medication review with follow-up to usual care compared to usual care alone for cardiovascular outpatients. MATERIALS AND METHODS: A state-transition microsimulation model was built to project outcomes over a lifetime time horizon. Inputs from a cluster randomized controlled trial conducted in primary health care centers in Chile with full-time pharmacists were used. Probabilities were estimated using patient-level data. Utilities and costs associated with each health state were obtained from the literature, whereas the intervention costs were retrieved from the trial. The public third-party payer perspective was used. Uncertainty was evaluated through one-way and probabilistic sensitivity analyses. RESULTS: For the base case analysis, an incremental cost-effectiveness ratio of $963 per quality-adjusted life-year was observed which was considered cost-effective. The results were robust to sensitivity analyses and were driven by decreased cardiovascular events resulting in lower mortality. CONCLUSIONS: Medication review with follow-up was deemed a cost-effective addition to usual care with low uncertainty. AU - Ahumada-Canale, A AU - Vargas, C AU - Martinez-Mardones, F AU - Plaza-Plaza, JC AU - Benrimoj, S AU - Garcia-Cardenas, V DA - 2021/09/16 DO - 10.1016/j.healthpol.2021.09.004 JO - Health Policy PB - Elsevier BV PY - 2021/09/16 TI - Cost-utility analysis of medication review with follow-up for cardiovascular outcomes: A microsimulation model. Y1 - 2021/09/16 Y2 - 2024/03/29 ER -